News and Announcements
Bioactive Annual Update 2016; New Compounds & Fractions Discovered, New Substance Pre-Screening Passed & Commercial Relationships Formed
- Published January 31, 2017 3:25PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Platform technology experts, Bioactive, continues to move forward with their capital raise along with achieving set targets during 2016:
- ‘Bioactive Therapeutics’, the Drug Discovery Division, has discovered new compounds and fractions to firmly establish a compound library within the key streams of inflammatory disorders and infectious diseases.
- ‘Bioactive Natural Health’, the Listed Medicine Division, has passed a rigorous TGA new substance pre-screening to proceed to full evaluation. Commercial relationships have been formed with some of the region’s largest companies and expect to be formalised to coincide with TGA approval in 2017.
- These opportunities collectively service the global market of 7 billion people. An investor exit is planned within 2 years.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
